[ad_1]
Allergan is taking this motion as a precaution following notification of lately up to date international security data in regards to the unusual incidence of breast implant-associated anaplastic massive cell lymphoma (BIA-ALCL) supplied by the U.S. Meals and Drug Administration (FDA).
[ad_2]
Source link
